检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:王文明[1]
出 处:《中国当代医药》2014年第10期75-76,79,共3页China Modern Medicine
摘 要:目的探讨甲泼尼龙冲击递减疗法治疗重症过敏性紫癜的临床效果。方法选取本院2010年9月~2013年9月收治的60例重症过敏性紫癜患者为研究对象,将其随机分成A组与B组,各30例。A组患者给予甲泼尼龙冲击疗法治疗,病情改善后改为口服递减治疗,B组患者给予甲泼尼龙常规治疗,观察两组患者的临床治疗效果。结果A组患者的皮疹消退时间为(6.86±3.25)d,腹泻缓解时间为(3.07±1.97)d,消化道出血消退时间为(3.76±2.56)d,肾损害恢复时间为(7.81±1.83)d,明显较B组患者的皮疹消退时间[(8.13±2,82)d]、腹泻缓解时间[(4.50±1.87)d]、消化道出血消退时间[(6.50±2.28)d]、肾损害恢复时间[(9.81±2.33)d]缩短(P〈O.05);两组患者治疗后其白介素一6(IL一6)、IL一8等均较治疗前有所改善且A组改善较B组明显(P〈O.05)。.结论甲泼尼龙冲击递减疗法治疗重症过敏性紫癜的临床效果较显著,其能有效改善患者的临床症状,具有较好的减轻肾脏损害的作用,值得推广应用。Objective To investigate the clinical effect of methylprednisolone pulse diminishing therapy in the treat- ment of severe allergic purpura. Methods 60 patients with severe allergic purpura admitted to our hospital from September 2010 to September 2013 were selected as the study subjects and randomly divided into the group A (n=30) and the group B (n=30).The group A received methylprednisolone pulse therapy and changed to oral diminishing treat- ment when the state of illness improved.The group B received conventional methylprednisolone treatment.The clinical treatment effect of the two groups was observed. Results The deflorescence time,diarrhea remission time,gastrointestinal bleeding vanishing time and renal damage recovery time of the group A was (6.86+3.25) days,(3.07+l.97) days,(3.76+ 2.56) days and (7.81~1.83) days respectively which were significantly shorter than the (8.13 ~ 2.82) days,(4.50 + 1.87) days,(6.50 ~ 2.28) days and (9.81 _+ 2.33) days of the group B (P〈0.05);after treatment,interleukin-6 (IL-6) and IL-8 of both groups improved compared to those before treatment (P〈0.05) and the group A was improved obviously compared to the group (P〈0.05). Conclusion Methylprednisolone pulse diminishing therapy shows more significant clinical effect in the treatment of severe allergic purpura and can effectively improve the patients' clinical symptom,and alleviate re- nal damage.It is worthy of promotion and application.
分 类 号:R554.6[医药卫生—血液循环系统疾病]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.15